Click for best price
Targeted Drugs for NSCLC Market Size, Share 2024
| Market size in 2024 |
US$ 18.9 billion
|
Forecast Market size by 2030 |
US$ 34.5 billion
|
| Growth Rate |
CAGR of 10.6% |
Number of Pages |
161 Pages |
The global Targeted Drugs for NSCLC market size was valued at US$ 18.9 billion in 2024 and is projected to reach US$ 34.5 billion by 2030, at a CAGR of 10.6% during the forecast period 2024-2030.
United States Targeted Drugs for NSCLC market size was valued at US$ 6.2 billion in 2024 and is projected to reach US$ 10.8 billion by 2030, at a CAGR of 9.7% during the forecast period 2024-2030.
Drugs specifically designed to target molecular abnormalities in non-small cell lung cancer.
Rapid growth driven by advances in precision medicine and biomarker testing. Increasing number of approved targeted therapies expanding treatment options. Ongoing research into new targets and combination strategies.
Report Overview
This report provides a deep insight into the global Targeted Drugs for NSCLC market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Targeted Drugs for NSCLC Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Targeted Drugs for NSCLC market in any manner.
Global Targeted Drugs for NSCLC Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
- Allergan
- Amgen
- ARIAD Pharmaceuticals (Takeda)
- Beacon Pharma Limited
- BeiGene
- Biocon
- Boehringer-Ingelheim
- Celgene Corporation
- Drug International Limted
- Fujifilm Kyowa Kirin Biologics
- Genvio Pharma Limited
- Hetero Drugs
- ImClone Systems (Eli Lilly)
- Incepta Pharmaceuticals
- Mylan
- Novartis
- Pfizer
- Reliance Lifesciences
- Roche
- AstraZeneca
- Cipla
- Teva
- OSI Pharmaceuticals
- Glenmark Pharmaceuticals
- Natco Pharma
Market Segmentation (by Type)
- Target EGFR
- Target ALK
- Target HER2
- Target ROS1
- Target BRAF
- Target MEK
- Target VEGFR2
- Target VEGF
- Target MET
Market Segmentation (by Application)
- Squamous Cell Carcinoma of NSCLC
- Adenocarcinoma of NSCLC
- Large Cell Carcinoma of NSCLC
Geographic Segmentation
- North America (USA, Canada, Mexico)
- Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
- South America (Brazil, Argentina, Columbia, Rest of South America)
- The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Targeted Drugs for NSCLC Market
- Overview of the regional outlook of the Targeted Drugs for NSCLC Market:
Key Reasons to Buy this Report:
Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
This enables you to anticipate market changes to remain ahead of your competitors
You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
Provision of market value (USD Billion) data for each segment and sub-segment
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Includes in-depth analysis of the market from various perspectives through Porter
| Report Attributes |
Report Details |
| Report Title |
Global Targeted Drugs for NSCLC Market Research Report 2024(Status and Outlook) |
| Market size in 2024 |
US$ 18.9 billion
|
| Forecast Market size by 2030 |
US$ 34.5 billion
|
| Growth Rate |
CAGR of 10.6% |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2023 |
| Forecast Year |
2031 |
| Number of Pages |
161 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
Table of Contents
1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Targeted Drugs for NSCLC
1.2 Key Market Segments
1.2.1 Targeted Drugs for NSCLC Segment by Type
1.2.2 Targeted Drugs for NSCLC Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Targeted Drugs for NSCLC Market Overview
2.1 Global Market Overview
2.1.1 Global Targeted Drugs for NSCLC Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Targeted Drugs for NSCLC Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 Targeted Drugs for NSCLC Market Competitive Landscape
3.1 Global Targeted Drugs for NSCLC Sales by Manufacturers (2019-2024)
3.2 Global Targeted Drugs for NSCLC Revenue Market Share by Manufacturers (2019-2024)
3.3 Targeted Drugs for NSCLC Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Targeted Drugs for NSCLC Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Targeted Drugs for NSCLC Sales Sites, Area Served, Product Type
3.6 Targeted Drugs for NSCLC Market Competitive Situation and Trends
3.6.1 Targeted Drugs for NSCLC Market Concentration Rate
3.6.2 Global 5 and 10 Largest Targeted Drugs for NSCLC Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 Targeted Drugs for NSCLC Industry Chain Analysis
4.1 Targeted Drugs for NSCLC Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of Targeted Drugs for NSCLC Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 Targeted Drugs for NSCLC Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Targeted Drugs for NSCLC Sales Market Share by Type (2019-2024)
6.3 Global Targeted Drugs for NSCLC Market Size Market Share by Type (2019-2024)
6.4 Global Targeted Drugs for NSCLC Price by Type (2019-2024)
7 Targeted Drugs for NSCLC Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Targeted Drugs for NSCLC Market Sales by Application (2019-2024)
7.3 Global Targeted Drugs for NSCLC Market Size (M USD) by Application (2019-2024)
7.4 Global Targeted Drugs for NSCLC Sales Growth Rate by Application (2019-2024)
8 Targeted Drugs for NSCLC Market Segmentation by Region
8.1 Global Targeted Drugs for NSCLC Sales by Region
8.1.1 Global Targeted Drugs for NSCLC Sales by Region
8.1.2 Global Targeted Drugs for NSCLC Sales Market Share by Region
8.2 North America
8.2.1 North America Targeted Drugs for NSCLC Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Targeted Drugs for NSCLC Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Targeted Drugs for NSCLC Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Targeted Drugs for NSCLC Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Targeted Drugs for NSCLC Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 Key Companies Profile
9.1 Allergan
9.1.1 Allergan Targeted Drugs for NSCLC Basic Information
9.1.2 Allergan Targeted Drugs for NSCLC Product Overview
9.1.3 Allergan Targeted Drugs for NSCLC Product Market Performance
9.1.4 Allergan Business Overview
9.1.5 Allergan Targeted Drugs for NSCLC SWOT Analysis
9.1.6 Allergan Recent Developments
9.2 Amgen
9.2.1 Amgen Targeted Drugs for NSCLC Basic Information
9.2.2 Amgen Targeted Drugs for NSCLC Product Overview
9.2.3 Amgen Targeted Drugs for NSCLC Product Market Performance
9.2.4 Amgen Business Overview
9.2.5 Amgen Targeted Drugs for NSCLC SWOT Analysis
9.2.6 Amgen Recent Developments
9.3 ARIAD Pharmaceuticals (Takeda)
9.3.1 ARIAD Pharmaceuticals (Takeda) Targeted Drugs for NSCLC Basic Information
9.3.2 ARIAD Pharmaceuticals (Takeda) Targeted Drugs for NSCLC Product Overview
9.3.3 ARIAD Pharmaceuticals (Takeda) Targeted Drugs for NSCLC Product Market Performance
9.3.4 ARIAD Pharmaceuticals (Takeda) Targeted Drugs for NSCLC SWOT Analysis
9.3.5 ARIAD Pharmaceuticals (Takeda) Business Overview
9.3.6 ARIAD Pharmaceuticals (Takeda) Recent Developments
9.4 Beacon Pharma Limited
9.4.1 Beacon Pharma Limited Targeted Drugs for NSCLC Basic Information
9.4.2 Beacon Pharma Limited Targeted Drugs for NSCLC Product Overview
9.4.3 Beacon Pharma Limited Targeted Drugs for NSCLC Product Market Performance
9.4.4 Beacon Pharma Limited Business Overview
9.4.5 Beacon Pharma Limited Recent Developments
9.5 BeiGene
9.5.1 BeiGene Targeted Drugs for NSCLC Basic Information
9.5.2 BeiGene Targeted Drugs for NSCLC Product Overview
9.5.3 BeiGene Targeted Drugs for NSCLC Product Market Performance
9.5.4 BeiGene Business Overview
9.5.5 BeiGene Recent Developments
9.6 Biocon
9.6.1 Biocon Targeted Drugs for NSCLC Basic Information
9.6.2 Biocon Targeted Drugs for NSCLC Product Overview
9.6.3 Biocon Targeted Drugs for NSCLC Product Market Performance
9.6.4 Biocon Business Overview
9.6.5 Biocon Recent Developments
9.7 Boehringer-Ingelheim
9.7.1 Boehringer-Ingelheim Targeted Drugs for NSCLC Basic Information
9.7.2 Boehringer-Ingelheim Targeted Drugs for NSCLC Product Overview
9.7.3 Boehringer-Ingelheim Targeted Drugs for NSCLC Product Market Performance
9.7.4 Boehringer-Ingelheim Business Overview
9.7.5 Boehringer-Ingelheim Recent Developments
9.8 Celgene Corporation
9.8.1 Celgene Corporation Targeted Drugs for NSCLC Basic Information
9.8.2 Celgene Corporation Targeted Drugs for NSCLC Product Overview
9.8.3 Celgene Corporation Targeted Drugs for NSCLC Product Market Performance
9.8.4 Celgene Corporation Business Overview
9.8.5 Celgene Corporation Recent Developments
9.9 Drug International Limted
9.9.1 Drug International Limted Targeted Drugs for NSCLC Basic Information
9.9.2 Drug International Limted Targeted Drugs for NSCLC Product Overview
9.9.3 Drug International Limted Targeted Drugs for NSCLC Product Market Performance
9.9.4 Drug International Limted Business Overview
9.9.5 Drug International Limted Recent Developments
9.10 Fujifilm Kyowa Kirin Biologics
9.10.1 Fujifilm Kyowa Kirin Biologics Targeted Drugs for NSCLC Basic Information
9.10.2 Fujifilm Kyowa Kirin Biologics Targeted Drugs for NSCLC Product Overview
9.10.3 Fujifilm Kyowa Kirin Biologics Targeted Drugs for NSCLC Product Market Performance
9.10.4 Fujifilm Kyowa Kirin Biologics Business Overview
9.10.5 Fujifilm Kyowa Kirin Biologics Recent Developments
9.11 Genvio Pharma Limited
9.11.1 Genvio Pharma Limited Targeted Drugs for NSCLC Basic Information
9.11.2 Genvio Pharma Limited Targeted Drugs for NSCLC Product Overview
9.11.3 Genvio Pharma Limited Targeted Drugs for NSCLC Product Market Performance
9.11.4 Genvio Pharma Limited Business Overview
9.11.5 Genvio Pharma Limited Recent Developments
9.12 Hetero Drugs
9.12.1 Hetero Drugs Targeted Drugs for NSCLC Basic Information
9.12.2 Hetero Drugs Targeted Drugs for NSCLC Product Overview
9.12.3 Hetero Drugs Targeted Drugs for NSCLC Product Market Performance
9.12.4 Hetero Drugs Business Overview
9.12.5 Hetero Drugs Recent Developments
9.13 ImClone Systems (Eli Lilly)
9.13.1 ImClone Systems (Eli Lilly) Targeted Drugs for NSCLC Basic Information
9.13.2 ImClone Systems (Eli Lilly) Targeted Drugs for NSCLC Product Overview
9.13.3 ImClone Systems (Eli Lilly) Targeted Drugs for NSCLC Product Market Performance
9.13.4 ImClone Systems (Eli Lilly) Business Overview
9.13.5 ImClone Systems (Eli Lilly) Recent Developments
9.14 Incepta Pharmaceuticals
9.14.1 Incepta Pharmaceuticals Targeted Drugs for NSCLC Basic Information
9.14.2 Incepta Pharmaceuticals Targeted Drugs for NSCLC Product Overview
9.14.3 Incepta Pharmaceuticals Targeted Drugs for NSCLC Product Market Performance
9.14.4 Incepta Pharmaceuticals Business Overview
9.14.5 Incepta Pharmaceuticals Recent Developments
9.15 Mylan
9.15.1 Mylan Targeted Drugs for NSCLC Basic Information
9.15.2 Mylan Targeted Drugs for NSCLC Product Overview
9.15.3 Mylan Targeted Drugs for NSCLC Product Market Performance
9.15.4 Mylan Business Overview
9.15.5 Mylan Recent Developments
9.16 Novartis
9.16.1 Novartis Targeted Drugs for NSCLC Basic Information
9.16.2 Novartis Targeted Drugs for NSCLC Product Overview
9.16.3 Novartis Targeted Drugs for NSCLC Product Market Performance
9.16.4 Novartis Business Overview
9.16.5 Novartis Recent Developments
9.17 Pfizer
9.17.1 Pfizer Targeted Drugs for NSCLC Basic Information
9.17.2 Pfizer Targeted Drugs for NSCLC Product Overview
9.17.3 Pfizer Targeted Drugs for NSCLC Product Market Performance
9.17.4 Pfizer Business Overview
9.17.5 Pfizer Recent Developments
9.18 Reliance Lifesciences
9.18.1 Reliance Lifesciences Targeted Drugs for NSCLC Basic Information
9.18.2 Reliance Lifesciences Targeted Drugs for NSCLC Product Overview
9.18.3 Reliance Lifesciences Targeted Drugs for NSCLC Product Market Performance
9.18.4 Reliance Lifesciences Business Overview
9.18.5 Reliance Lifesciences Recent Developments
9.19 Roche
9.19.1 Roche Targeted Drugs for NSCLC Basic Information
9.19.2 Roche Targeted Drugs for NSCLC Product Overview
9.19.3 Roche Targeted Drugs for NSCLC Product Market Performance
9.19.4 Roche Business Overview
9.19.5 Roche Recent Developments
9.20 AstraZeneca
9.20.1 AstraZeneca Targeted Drugs for NSCLC Basic Information
9.20.2 AstraZeneca Targeted Drugs for NSCLC Product Overview
9.20.3 AstraZeneca Targeted Drugs for NSCLC Product Market Performance
9.20.4 AstraZeneca Business Overview
9.20.5 AstraZeneca Recent Developments
9.21 Cipla
9.21.1 Cipla Targeted Drugs for NSCLC Basic Information
9.21.2 Cipla Targeted Drugs for NSCLC Product Overview
9.21.3 Cipla Targeted Drugs for NSCLC Product Market Performance
9.21.4 Cipla Business Overview
9.21.5 Cipla Recent Developments
9.22 Teva
9.22.1 Teva Targeted Drugs for NSCLC Basic Information
9.22.2 Teva Targeted Drugs for NSCLC Product Overview
9.22.3 Teva Targeted Drugs for NSCLC Product Market Performance
9.22.4 Teva Business Overview
9.22.5 Teva Recent Developments
9.23 OSI Pharmaceuticals
9.23.1 OSI Pharmaceuticals Targeted Drugs for NSCLC Basic Information
9.23.2 OSI Pharmaceuticals Targeted Drugs for NSCLC Product Overview
9.23.3 OSI Pharmaceuticals Targeted Drugs for NSCLC Product Market Performance
9.23.4 OSI Pharmaceuticals Business Overview
9.23.5 OSI Pharmaceuticals Recent Developments
9.24 Glenmark Pharmaceuticals
9.24.1 Glenmark Pharmaceuticals Targeted Drugs for NSCLC Basic Information
9.24.2 Glenmark Pharmaceuticals Targeted Drugs for NSCLC Product Overview
9.24.3 Glenmark Pharmaceuticals Targeted Drugs for NSCLC Product Market Performance
9.24.4 Glenmark Pharmaceuticals Business Overview
9.24.5 Glenmark Pharmaceuticals Recent Developments
9.25 Natco Pharma
9.25.1 Natco Pharma Targeted Drugs for NSCLC Basic Information
9.25.2 Natco Pharma Targeted Drugs for NSCLC Product Overview
9.25.3 Natco Pharma Targeted Drugs for NSCLC Product Market Performance
9.25.4 Natco Pharma Business Overview
9.25.5 Natco Pharma Recent Developments
10 Targeted Drugs for NSCLC Market Forecast by Region
10.1 Global Targeted Drugs for NSCLC Market Size Forecast
10.2 Global Targeted Drugs for NSCLC Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Targeted Drugs for NSCLC Market Size Forecast by Country
10.2.3 Asia Pacific Targeted Drugs for NSCLC Market Size Forecast by Region
10.2.4 South America Targeted Drugs for NSCLC Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Targeted Drugs for NSCLC by Country
11 Forecast Market by Type and by Application (2025-2030)
11.1 Global Targeted Drugs for NSCLC Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Targeted Drugs for NSCLC by Type (2025-2030)
11.1.2 Global Targeted Drugs for NSCLC Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Targeted Drugs for NSCLC by Type (2025-2030)
11.2 Global Targeted Drugs for NSCLC Market Forecast by Application (2025-2030)
11.2.1 Global Targeted Drugs for NSCLC Sales (K Units) Forecast by Application
11.2.2 Global Targeted Drugs for NSCLC Market Size (M USD) Forecast by Application (2025-2030)
12 Conclusion and Key Findings
LIST OF TABLES & FIGURES
List of Tables
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Targeted Drugs for NSCLC Market Size Comparison by Region (M USD)
Table 5. Global Targeted Drugs for NSCLC Sales (K Units) by Manufacturers (2019-2024)
Table 6. Global Targeted Drugs for NSCLC Sales Market Share by Manufacturers (2019-2024)
Table 7. Global Targeted Drugs for NSCLC Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global Targeted Drugs for NSCLC Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Targeted Drugs for NSCLC as of 2022)
Table 10. Global Market Targeted Drugs for NSCLC Average Price (USD/Unit) of Key Manufacturers (2019-2024)
Table 11. Manufacturers Targeted Drugs for NSCLC Sales Sites and Area Served
Table 12. Manufacturers Targeted Drugs for NSCLC Product Type
Table 13. Global Targeted Drugs for NSCLC Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Targeted Drugs for NSCLC
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Targeted Drugs for NSCLC Market Challenges
Table 22. Global Targeted Drugs for NSCLC Sales by Type (K Units)
Table 23. Global Targeted Drugs for NSCLC Market Size by Type (M USD)
Table 24. Global Targeted Drugs for NSCLC Sales (K Units) by Type (2019-2024)
Table 25. Global Targeted Drugs for NSCLC Sales Market Share by Type (2019-2024)
Table 26. Global Targeted Drugs for NSCLC Market Size (M USD) by Type (2019-2024)
Table 27. Global Targeted Drugs for NSCLC Market Size Share by Type (2019-2024)
Table 28. Global Targeted Drugs for NSCLC Price (USD/Unit) by Type (2019-2024)
Table 29. Global Targeted Drugs for NSCLC Sales (K Units) by Application
Table 30. Global Targeted Drugs for NSCLC Market Size by Application
Table 31. Global Targeted Drugs for NSCLC Sales by Application (2019-2024) & (K Units)
Table 32. Global Targeted Drugs for NSCLC Sales Market Share by Application (2019-2024)
Table 33. Global Targeted Drugs for NSCLC Sales by Application (2019-2024) & (M USD)
Table 34. Global Targeted Drugs for NSCLC Market Share by Application (2019-2024)
Table 35. Global Targeted Drugs for NSCLC Sales Growth Rate by Application (2019-2024)
Table 36. Global Targeted Drugs for NSCLC Sales by Region (2019-2024) & (K Units)
Table 37. Global Targeted Drugs for NSCLC Sales Market Share by Region (2019-2024)
Table 38. North America Targeted Drugs for NSCLC Sales by Country (2019-2024) & (K Units)
Table 39. Europe Targeted Drugs for NSCLC Sales by Country (2019-2024) & (K Units)
Table 40. Asia Pacific Targeted Drugs for NSCLC Sales by Region (2019-2024) & (K Units)
Table 41. South America Targeted Drugs for NSCLC Sales by Country (2019-2024) & (K Units)
Table 42. Middle East and Africa Targeted Drugs for NSCLC Sales by Region (2019-2024) & (K Units)
Table 43. Allergan Targeted Drugs for NSCLC Basic Information
Table 44. Allergan Targeted Drugs for NSCLC Product Overview
Table 45. Allergan Targeted Drugs for NSCLC Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 46. Allergan Business Overview
Table 47. Allergan Targeted Drugs for NSCLC SWOT Analysis
Table 48. Allergan Recent Developments
Table 49. Amgen Targeted Drugs for NSCLC Basic Information
Table 50. Amgen Targeted Drugs for NSCLC Product Overview
Table 51. Amgen Targeted Drugs for NSCLC Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 52. Amgen Business Overview
Table 53. Amgen Targeted Drugs for NSCLC SWOT Analysis
Table 54. Amgen Recent Developments
Table 55. ARIAD Pharmaceuticals (Takeda) Targeted Drugs for NSCLC Basic Information
Table 56. ARIAD Pharmaceuticals (Takeda) Targeted Drugs for NSCLC Product Overview
Table 57. ARIAD Pharmaceuticals (Takeda) Targeted Drugs for NSCLC Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 58. ARIAD Pharmaceuticals (Takeda) Targeted Drugs for NSCLC SWOT Analysis
Table 59. ARIAD Pharmaceuticals (Takeda) Business Overview
Table 60. ARIAD Pharmaceuticals (Takeda) Recent Developments
Table 61. Beacon Pharma Limited Targeted Drugs for NSCLC Basic Information
Table 62. Beacon Pharma Limited Targeted Drugs for NSCLC Product Overview
Table 63. Beacon Pharma Limited Targeted Drugs for NSCLC Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 64. Beacon Pharma Limited Business Overview
Table 65. Beacon Pharma Limited Recent Developments
Table 66. BeiGene Targeted Drugs for NSCLC Basic Information
Table 67. BeiGene Targeted Drugs for NSCLC Product Overview
Table 68. BeiGene Targeted Drugs for NSCLC Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 69. BeiGene Business Overview
Table 70. BeiGene Recent Developments
Table 71. Biocon Targeted Drugs for NSCLC Basic Information
Table 72. Biocon Targeted Drugs for NSCLC Product Overview
Table 73. Biocon Targeted Drugs for NSCLC Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 74. Biocon Business Overview
Table 75. Biocon Recent Developments
Table 76. Boehringer-Ingelheim Targeted Drugs for NSCLC Basic Information
Table 77. Boehringer-Ingelheim Targeted Drugs for NSCLC Product Overview
Table 78. Boehringer-Ingelheim Targeted Drugs for NSCLC Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 79. Boehringer-Ingelheim Business Overview
Table 80. Boehringer-Ingelheim Recent Developments
Table 81. Celgene Corporation Targeted Drugs for NSCLC Basic Information
Table 82. Celgene Corporation Targeted Drugs for NSCLC Product Overview
Table 83. Celgene Corporation Targeted Drugs for NSCLC Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 84. Celgene Corporation Business Overview
Table 85. Celgene Corporation Recent Developments
Table 86. Drug International Limted Targeted Drugs for NSCLC Basic Information
Table 87. Drug International Limted Targeted Drugs for NSCLC Product Overview
Table 88. Drug International Limted Targeted Drugs for NSCLC Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 89. Drug International Limted Business Overview
Table 90. Drug International Limted Recent Developments
Table 91. Fujifilm Kyowa Kirin Biologics Targeted Drugs for NSCLC Basic Information
Table 92. Fujifilm Kyowa Kirin Biologics Targeted Drugs for NSCLC Product Overview
Table 93. Fujifilm Kyowa Kirin Biologics Targeted Drugs for NSCLC Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 94. Fujifilm Kyowa Kirin Biologics Business Overview
Table 95. Fujifilm Kyowa Kirin Biologics Recent Developments
Table 96. Genvio Pharma Limited Targeted Drugs for NSCLC Basic Information
Table 97. Genvio Pharma Limited Targeted Drugs for NSCLC Product Overview
Table 98. Genvio Pharma Limited Targeted Drugs for NSCLC Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 99. Genvio Pharma Limited Business Overview
Table 100. Genvio Pharma Limited Recent Developments
Table 101. Hetero Drugs Targeted Drugs for NSCLC Basic Information
Table 102. Hetero Drugs Targeted Drugs for NSCLC Product Overview
Table 103. Hetero Drugs Targeted Drugs for NSCLC Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 104. Hetero Drugs Business Overview
Table 105. Hetero Drugs Recent Developments
Table 106. ImClone Systems (Eli Lilly) Targeted Drugs for NSCLC Basic Information
Table 107. ImClone Systems (Eli Lilly) Targeted Drugs for NSCLC Product Overview
Table 108. ImClone Systems (Eli Lilly) Targeted Drugs for NSCLC Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 109. ImClone Systems (Eli Lilly) Business Overview
Table 110. ImClone Systems (Eli Lilly) Recent Developments
Table 111. Incepta Pharmaceuticals Targeted Drugs for NSCLC Basic Information
Table 112. Incepta Pharmaceuticals Targeted Drugs for NSCLC Product Overview
Table 113. Incepta Pharmaceuticals Targeted Drugs for NSCLC Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 114. Incepta Pharmaceuticals Business Overview
Table 115. Incepta Pharmaceuticals Recent Developments
Table 116. Mylan Targeted Drugs for NSCLC Basic Information
Table 117. Mylan Targeted Drugs for NSCLC Product Overview
Table 118. Mylan Targeted Drugs for NSCLC Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 119. Mylan Business Overview
Table 120. Mylan Recent Developments
Table 121. Novartis Targeted Drugs for NSCLC Basic Information
Table 122. Novartis Targeted Drugs for NSCLC Product Overview
Table 123. Novartis Targeted Drugs for NSCLC Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 124. Novartis Business Overview
Table 125. Novartis Recent Developments
Table 126. Pfizer Targeted Drugs for NSCLC Basic Information
Table 127. Pfizer Targeted Drugs for NSCLC Product Overview
Table 128. Pfizer Targeted Drugs for NSCLC Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 129. Pfizer Business Overview
Table 130. Pfizer Recent Developments
Table 131. Reliance Lifesciences Targeted Drugs for NSCLC Basic Information
Table 132. Reliance Lifesciences Targeted Drugs for NSCLC Product Overview
Table 133. Reliance Lifesciences Targeted Drugs for NSCLC Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 134. Reliance Lifesciences Business Overview
Table 135. Reliance Lifesciences Recent Developments
Table 136. Roche Targeted Drugs for NSCLC Basic Information
Table 137. Roche Targeted Drugs for NSCLC Product Overview
Table 138. Roche Targeted Drugs for NSCLC Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 139. Roche Business Overview
Table 140. Roche Recent Developments
Table 141. AstraZeneca Targeted Drugs for NSCLC Basic Information
Table 142. AstraZeneca Targeted Drugs for NSCLC Product Overview
Table 143. AstraZeneca Targeted Drugs for NSCLC Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 144. AstraZeneca Business Overview
Table 145. AstraZeneca Recent Developments
Table 146. Cipla Targeted Drugs for NSCLC Basic Information
Table 147. Cipla Targeted Drugs for NSCLC Product Overview
Table 148. Cipla Targeted Drugs for NSCLC Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 149. Cipla Business Overview
Table 150. Cipla Recent Developments
Table 151. Teva Targeted Drugs for NSCLC Basic Information
Table 152. Teva Targeted Drugs for NSCLC Product Overview
Table 153. Teva Targeted Drugs for NSCLC Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 154. Teva Business Overview
Table 155. Teva Recent Developments
Table 156. OSI Pharmaceuticals Targeted Drugs for NSCLC Basic Information
Table 157. OSI Pharmaceuticals Targeted Drugs for NSCLC Product Overview
Table 158. OSI Pharmaceuticals Targeted Drugs for NSCLC Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 159. OSI Pharmaceuticals Business Overview
Table 160. OSI Pharmaceuticals Recent Developments
Table 161. Glenmark Pharmaceuticals Targeted Drugs for NSCLC Basic Information
Table 162. Glenmark Pharmaceuticals Targeted Drugs for NSCLC Product Overview
Table 163. Glenmark Pharmaceuticals Targeted Drugs for NSCLC Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 164. Glenmark Pharmaceuticals Business Overview
Table 165. Glenmark Pharmaceuticals Recent Developments
Table 166. Natco Pharma Targeted Drugs for NSCLC Basic Information
Table 167. Natco Pharma Targeted Drugs for NSCLC Product Overview
Table 168. Natco Pharma Targeted Drugs for NSCLC Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
Table 169. Natco Pharma Business Overview
Table 170. Natco Pharma Recent Developments
Table 171. Global Targeted Drugs for NSCLC Sales Forecast by Region (2025-2030) & (K Units)
Table 172. Global Targeted Drugs for NSCLC Market Size Forecast by Region (2025-2030) & (M USD)
Table 173. North America Targeted Drugs for NSCLC Sales Forecast by Country (2025-2030) & (K Units)
Table 174. North America Targeted Drugs for NSCLC Market Size Forecast by Country (2025-2030) & (M USD)
Table 175. Europe Targeted Drugs for NSCLC Sales Forecast by Country (2025-2030) & (K Units)
Table 176. Europe Targeted Drugs for NSCLC Market Size Forecast by Country (2025-2030) & (M USD)
Table 177. Asia Pacific Targeted Drugs for NSCLC Sales Forecast by Region (2025-2030) & (K Units)
Table 178. Asia Pacific Targeted Drugs for NSCLC Market Size Forecast by Region (2025-2030) & (M USD)
Table 179. South America Targeted Drugs for NSCLC Sales Forecast by Country (2025-2030) & (K Units)
Table 180. South America Targeted Drugs for NSCLC Market Size Forecast by Country (2025-2030) & (M USD)
Table 181. Middle East and Africa Targeted Drugs for NSCLC Consumption Forecast by Country (2025-2030) & (Units)
Table 182. Middle East and Africa Targeted Drugs for NSCLC Market Size Forecast by Country (2025-2030) & (M USD)
Table 183. Global Targeted Drugs for NSCLC Sales Forecast by Type (2025-2030) & (K Units)
Table 184. Global Targeted Drugs for NSCLC Market Size Forecast by Type (2025-2030) & (M USD)
Table 185. Global Targeted Drugs for NSCLC Price Forecast by Type (2025-2030) & (USD/Unit)
Table 186. Global Targeted Drugs for NSCLC Sales (K Units) Forecast by Application (2025-2030)
Table 187. Global Targeted Drugs for NSCLC Market Size Forecast by Application (2025-2030) & (M USD)
List of Figures
Figure 1. Product Picture of Targeted Drugs for NSCLC
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Targeted Drugs for NSCLC Market Size (M USD), 2019-2030
Figure 5. Global Targeted Drugs for NSCLC Market Size (M USD) (2019-2030)
Figure 6. Global Targeted Drugs for NSCLC Sales (K Units) & (2019-2030)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Targeted Drugs for NSCLC Market Size by Country (M USD)
Figure 11. Targeted Drugs for NSCLC Sales Share by Manufacturers in 2023
Figure 12. Global Targeted Drugs for NSCLC Revenue Share by Manufacturers in 2023
Figure 13. Targeted Drugs for NSCLC Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Targeted Drugs for NSCLC Average Price (USD/Unit) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Targeted Drugs for NSCLC Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Targeted Drugs for NSCLC Market Share by Type
Figure 18. Sales Market Share of Targeted Drugs for NSCLC by Type (2019-2024)
Figure 19. Sales Market Share of Targeted Drugs for NSCLC by Type in 2023
Figure 20. Market Size Share of Targeted Drugs for NSCLC by Type (2019-2024)
Figure 21. Market Size Market Share of Targeted Drugs for NSCLC by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Targeted Drugs for NSCLC Market Share by Application
Figure 24. Global Targeted Drugs for NSCLC Sales Market Share by Application (2019-2024)
Figure 25. Global Targeted Drugs for NSCLC Sales Market Share by Application in 2023
Figure 26. Global Targeted Drugs for NSCLC Market Share by Application (2019-2024)
Figure 27. Global Targeted Drugs for NSCLC Market Share by Application in 2023
Figure 28. Global Targeted Drugs for NSCLC Sales Growth Rate by Application (2019-2024)
Figure 29. Global Targeted Drugs for NSCLC Sales Market Share by Region (2019-2024)
Figure 30. North America Targeted Drugs for NSCLC Sales and Growth Rate (2019-2024) & (K Units)
Figure 31. North America Targeted Drugs for NSCLC Sales Market Share by Country in 2023
Figure 32. U.S. Targeted Drugs for NSCLC Sales and Growth Rate (2019-2024) & (K Units)
Figure 33. Canada Targeted Drugs for NSCLC Sales (K Units) and Growth Rate (2019-2024)
Figure 34. Mexico Targeted Drugs for NSCLC Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe Targeted Drugs for NSCLC Sales and Growth Rate (2019-2024) & (K Units)
Figure 36. Europe Targeted Drugs for NSCLC Sales Market Share by Country in 2023
Figure 37. Germany Targeted Drugs for NSCLC Sales and Growth Rate (2019-2024) & (K Units)
Figure 38. France Targeted Drugs for NSCLC Sales and Growth Rate (2019-2024) & (K Units)
Figure 39. U.K. Targeted Drugs for NSCLC Sales and Growth Rate (2019-2024) & (K Units)
Figure 40. Italy Targeted Drugs for NSCLC Sales and Growth Rate (2019-2024) & (K Units)
Figure 41. Russia Targeted Drugs for NSCLC Sales and Growth Rate (2019-2024) & (K Units)
Figure 42. Asia Pacific Targeted Drugs for NSCLC Sales and Growth Rate (K Units)
Figure 43. Asia Pacific Targeted Drugs for NSCLC Sales Market Share by Region in 2023
Figure 44. China Targeted Drugs for NSCLC Sales and Growth Rate (2019-2024) & (K Units)
Figure 45. Japan Targeted Drugs for NSCLC Sales and Growth Rate (2019-2024) & (K Units)
Figure 46. South Korea Targeted Drugs for NSCLC Sales and Growth Rate (2019-2024) & (K Units)
Figure 47. India Targeted Drugs for NSCLC Sales and Growth Rate (2019-2024) & (K Units)
Figure 48. Southeast Asia Targeted Drugs for NSCLC Sales and Growth Rate (2019-2024) & (K Units)
Figure 49. South America Targeted Drugs for NSCLC Sales and Growth Rate (K Units)
Figure 50. South America Targeted Drugs for NSCLC Sales Market Share by Country in 2023
Figure 51. Brazil Targeted Drugs for NSCLC Sales and Growth Rate (2019-2024) & (K Units)
Figure 52. Argentina Targeted Drugs for NSCLC Sales and Growth Rate (2019-2024) & (K Units)
Figure 53. Columbia Targeted Drugs for NSCLC Sales and Growth Rate (2019-2024) & (K Units)
Figure 54. Middle East and Africa Targeted Drugs for NSCLC Sales and Growth Rate (K Units)
Figure 55. Middle East and Africa Targeted Drugs for NSCLC Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Targeted Drugs for NSCLC Sales and Growth Rate (2019-2024) & (K Units)
Figure 57. UAE Targeted Drugs for NSCLC Sales and Growth Rate (2019-2024) & (K Units)
Figure 58. Egypt Targeted Drugs for NSCLC Sales and Growth Rate (2019-2024) & (K Units)
Figure 59. Nigeria Targeted Drugs for NSCLC Sales and Growth Rate (2019-2024) & (K Units)
Figure 60. South Africa Targeted Drugs for NSCLC Sales and Growth Rate (2019-2024) & (K Units)
Figure 61. Global Targeted Drugs for NSCLC Sales Forecast by Volume (2019-2030) & (K Units)
Figure 62. Global Targeted Drugs for NSCLC Market Size Forecast by Value (2019-2030) & (M USD)
Figure 63. Global Targeted Drugs for NSCLC Sales Market Share Forecast by Type (2025-2030)
Figure 64. Global Targeted Drugs for NSCLC Market Share Forecast by Type (2025-2030)
Figure 65. Global Targeted Drugs for NSCLC Sales Forecast by Application (2025-2030)
Figure 66. Global Targeted Drugs for NSCLC Market Share Forecast by Application (2025-2030)
